Evidence map›Paper›PMID 40169520›Full record

ArticleApplied health economics and health policy2025

Alternative Payment Models for Innovative Medicines: A Framework for Effective Implementation.

Frederick McElwee, Amanda Cole, Gomathi Kaliappan, Andrea Masters, Lotte Steuten

Abstract read
In one paragraph

Article in Applied health economics and health policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Frederick McElweeOffice of Health Economics, 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB, UK.ORCID 0009-0002-1657-1089
Amanda ColeOffice of Health Economics, 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB, UK. acole@ohe.org.ORCID 0000-0001-6179-7752
Gomathi KaliappanF. Hoffmann-La Roche AG, Basel, Switzerland.
Andrea MastersF. Hoffmann-La Roche AG, Toronto, Canada.
Lotte SteutenOffice of Health Economics, 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB, UK.ORCID 0000-0002-5688-236X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scientific advancements offer significant opportunities for better patient outcomes, but also present new challenges for value assessment, affordability and access. Alternative payment models (APMs) can offer solutions to the ensuing payer challenges. However, a comprehensive framework that matches the spectrum of challenges with the right solution, and places them within a framework for implementation, is currently missing. To fill this gap, we propose evidence-based steps for the effective selection and implementation of APMs. First, contracting challenges should be identified and mapped to potential APM solutions. We developed a decision guide that can serve as a starting point to articulate core problems and map these to APM solutions. The main problem categories identified are: budget impact and uncertainty, value uncertainty, and the scope of value assessment and negotiation. Sub-categories include affordability, uncertainty of effectiveness, and patient heterogeneity, which map onto APM solutions such as outcome-based agreements, instalments, and subscription models. Just as important are the subsequent identification and assessment of the feasibility of potential solutions as well as collaboration to reach agreement on the terms of the APM and lay the groundwork for effective implementation. We adduce recent examples of APM implementation as evidence of how commonly cited implementation barriers can be overcome by applying pragmatic design choices and collaboration. This step-by-step framework can aid payers and manufacturers in the process of effectively identifying, agreeing on, and implementing APMs to advance patient access to cost-effective medicines, while at the same time providing appropriate incentives to support future innovation.

Indexed as

Reimbursement MechanismsCost-Benefit AnalysisHumans

Identifiers

PMID40169520
PMCPMC12170698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.